Study study type PathologyT1T0Patientssample sizesROB Results

non squamous - mNSCLC - L1 - Wild Type (WT) metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) non squamous cell - mNSCLC - L1 non squamous - mNSCLC - L1 - Wild Type (WT)

versus pemetrexed plus platin
atezolizumab plus pemetrexed and platin
IMpower-132 (WT) unpublished
 
NCT02657434
RCTnon squamous - mNSCLC - L1 - Wild Type (WT)Atezolizumab (induction and maintenance) plus pemetrexed plus platinepemetrexed plus platineChemotherapy-naive patients with Stage IV non-squamous NSCLC without EGFR or ALK genetic alteration292 / 286NA
conclusif
  • inconclusive 19 % decrease in deaths (OS) (PE)
  • demonstrated 40 % decrease in progression or deaths (PFS) (PE)